Evidence map›Paper›PMID 42420824›Full record

ArticleBMC microbiology2026

Phenotypic and molecular characterization of carbapenem resistance among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii.

Gopiram Syangtan, Laxmi Kant Khanal, Shrijana Bista, Arun Bahadur Chand, Prabin Dawadi, Binod Rayamajhee, Reshma Tuladhar, Shiba Kumar Rai, Dev Raj Joshi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gopiram SyangtanShi-Gan International College of Science and Technology (SICOST), Tribhuvan University, Kathmandu, Bagmati, Nepal. syangtangopiram1@gmail.com.ORCID http://orcid.org/0000-0001-5536-7828
Laxmi Kant KhanalShi-Gan International College of Science and Technology (SICOST), Tribhuvan University, Kathmandu, Bagmati, Nepal.
Shrijana BistaCentral Department of Microbiology, Tribhuvan University, Kathmandu, Bagmati, Nepal.ORCID http://orcid.org/0000-0002-6885-3881
Arun Bahadur ChandDepartment of Microbiology, KIST Medical College and Teaching Hospital, Lalitpur, Bagmati, Nepal.
Prabin DawadiCentral Department of Microbiology, Tribhuvan University, Kathmandu, Bagmati, Nepal.
Binod RayamajheeFaculty of Medicine, Health and Human Sciences, Macquarie University, Macquarie, Australia.
Reshma TuladharCentral Department of Microbiology, Tribhuvan University, Kathmandu, Bagmati, Nepal.
Shiba Kumar RaiShi-Gan International College of Science and Technology (SICOST), Tribhuvan University, Kathmandu, Bagmati, Nepal.
Dev Raj JoshiCentral Department of Microbiology, Tribhuvan University, Kathmandu, Bagmati, Nepal.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCarbapenem-resistant Pseudomonas aeruginosa (CRPA) and Acinetobacter baumannii (CRAB) were listed on the WHO bacterial priority pathogens list in 2017. These gram-negative bacteria often cause healthcare-associated infections (HAIs), which pose an increasing threat to public health. This study aimed to isolate and identify CRPAs and CRABs from a tertiary care hospital in central Nepal and characterize carbapenem resistance genes at the molecular level. MATERIALS AND

methodsA total of 59 isolates, including 27 Pseudomonas aeruginosa and 32 Acinetobacter baumannii, were collected from different clinical samples from April 2021 to December 2022. Antibiotic susceptibility was determined via the Kirby disc diffusion method. The modified carbapenem inactivation method (mCIM) was used for phenotypic confirmation of carbapenem resistance. Conventional polymerase chain reaction (PCR) was used to detect carbapenem resistance genes.

resultsAmong the 59 isolates, 76.3% were multidrug resistant (MDR), 63.0% were extended-spectrum beta-lactamase (ESBL), and 62.7% were carbapenem resistant. Among the carbapenem-resistant isolates (n = 37), 75.7% of metallo-beta-lactamase (MBL) producers and 70.3% carried at least one carbapenem resistance gene. The bla

conclusionThis study highlights a significant burden of MDR and carbapenem-resistant P. aeruginosa and A. baumannii, with the co-occurrence of carbapenem resistance genes, in a clinical setting in Nepal. Our findings suggest that active surveillance of antibiotic resistance in pathogens could inform clinicians and healthcare providers about the treatment of infections.

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsCarbapenemsPseudomonas aeruginosaAcinetobacter InfectionsBacterial Proteinsbeta-LactamasesDrug Resistance, Multiple, BacterialHumansMicrobial Sensitivity TestsNepalPhenotypePseudomonas InfectionsAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCarbapenemsA. baumanniiCarbapenem resistanceCo-occurrenceESBLsMBLNepalP. aeruginosa

Identifiers

PMID42420824
PMCPMC13628859

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.